Among the 10 candidate genes selected for validation, FFAR2, ITGA2B, SOCS3, and KCNJ15 exhibited statistically significant differential expression.<h4>Conclusion</h4>Our findings suggest that loss of response may be potentially associated with pro-inflammatory pathways independent of the drug's action pathways, as well as a "pro-fibrotic immune microenvironment" linked to intestinal strictures. Here, FFAR2 is linked to stricture.